Which has preferable valuation & earnings, ABVX or ROIV?

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Roivant Sciences $8.26M 2,916.39 -$299.77M -$0.53 N/A

Is ABVX or ROIV more profitable?

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media prefer ABVX or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than Abivax. MarketBeat recorded 5 mentions for Roivant Sciences and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Roivant Sciences' score of 0.89 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or BNTX more profitable?

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% BioNTech -63.54% -6.86% -6.00%

Does the media prefer ABVX or BNTX?

In the previous week, BioNTech had 32 more articles in the media than Abivax. MarketBeat recorded 34 mentions for BioNTech and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat BioNTech's score of 0.40 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 10 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral

Does the media prefer ABVX or UTHR?

In the previous week, United Therapeutics had 16 more articles in the media than Abivax. MarketBeat recorded 18 mentions for United Therapeutics and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat United Therapeutics' score of 0.74 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ABVX or GMAB?

Genmab A/S has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Genmab A/S $3.72B 6.13 $963M $1.27 28.80

Is ABVX or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Abivax's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Genmab A/S 19.08% 14.89% 7.73%

Does the media prefer ABVX or GMAB?

In the previous week, Genmab A/S had 18 more articles in the media than Abivax. MarketBeat recorded 20 mentions for Genmab A/S and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Genmab A/S's score of 0.35 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Genmab A/S 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ABVX or INCY?

Incyte has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Incyte $5.14B 4.28 $1.29B $7.85 13.84

Is ABVX or INCY more profitable?

Incyte has a net margin of 27.71% compared to Abivax's net margin of 0.00%. Incyte's return on equity of 29.93% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Incyte 27.71% 29.93% 22.88%

Does the media refer more to ABVX or INCY?

In the previous week, Incyte had 10 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Incyte and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Incyte's score of 0.28 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Incyte 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Abivax (ABVX) Competitors

$86.22 -0.72 (-0.83%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$86.67 +0.45 (+0.52%)

As of 04:02 AM Eastern

Compare

ABVX vs. ROIV, BNTX, UTHR, GMAB, and INCY

Should you buy Abivax stock or one of its competitors? Abivax's main competitors and comparable companies include Roivant Sciences (ROIV), BioNTech (BNTX), United Therapeutics (UTHR), Genmab A/S (GMAB), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abivax compare to Roivant Sciences?

Abivax (NASDAQ:ABVX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Roivant Sciences had 3 more articles in the media than Abivax. MarketBeat recorded 5 mentions for Roivant Sciences and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Roivant Sciences' score of 0.89 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Abivax currently has a consensus target price of $156.69, suggesting a potential upside of 81.74%. Roivant Sciences has a consensus target price of $45.64, suggesting a potential upside of 36.84%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts plainly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Roivant Sciences	$8.26M	2,916.39	-$299.77M	-$0.53	N/A

47.9% of Abivax shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Roivant Sciences beats Abivax on 8 of the 14 factors compared between the two stocks.

How does Abivax compare to BioNTech?

Abivax (NASDAQ:ABVX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Abivax presently has a consensus price target of $156.69, suggesting a potential upside of 81.74%. BioNTech has a consensus price target of $125.69, suggesting a potential upside of 41.21%. Given Abivax's stronger consensus rating and higher possible upside, equities analysts plainly believe Abivax is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

Abivax has higher earnings, but lower revenue than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
BioNTech	$3.25B	6.93	-$1.29B	-$7.83	N/A

Abivax has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
BioNTech	-63.54%	-6.86%	-6.00%

47.9% of Abivax shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, BioNTech had 32 more articles in the media than Abivax. MarketBeat recorded 34 mentions for BioNTech and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat BioNTech's score of 0.40 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	10 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Neutral

Summary

Abivax beats BioNTech on 8 of the 15 factors compared between the two stocks.

How does Abivax compare to United Therapeutics?

Abivax (NASDAQ:ABVX) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

United Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
United Therapeutics	$3.18B	7.32	$1.33B	$27.95	19.44

United Therapeutics has a net margin of 41.56% compared to Abivax's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
United Therapeutics	41.56%	20.18%	17.98%

Abivax currently has a consensus target price of $156.69, suggesting a potential upside of 81.74%. United Therapeutics has a consensus target price of $627.31, suggesting a potential upside of 15.44%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Abivax is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

47.9% of Abivax shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 16 more articles in the media than Abivax. MarketBeat recorded 18 mentions for United Therapeutics and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat United Therapeutics' score of 0.74 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Summary

United Therapeutics beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Abivax compare to Genmab A/S?

Abivax (NASDAQ:ABVX) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Abivax presently has a consensus price target of $156.69, suggesting a potential upside of 81.74%. Genmab A/S has a consensus price target of $42.50, suggesting a potential upside of 16.22%. Given Abivax's stronger consensus rating and higher probable upside, research analysts clearly believe Abivax is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has a net margin of 19.08% compared to Abivax's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Genmab A/S	19.08%	14.89%	7.73%

Abivax has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Genmab A/S had 18 more articles in the media than Abivax. MarketBeat recorded 20 mentions for Genmab A/S and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Genmab A/S's score of 0.35 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.9% of Abivax shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Genmab A/S	$3.72B	6.13	$963M	$1.27	28.80

Summary

Genmab A/S beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Abivax compare to Incyte?

Abivax (NASDAQ:ABVX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Abivax has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Incyte has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Abivax's net margin of 0.00%. Incyte's return on equity of 29.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Incyte	27.71%	29.93%	22.88%

In the previous week, Incyte had 10 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Incyte and 2 mentions for Abivax. Abivax's average media sentiment score of 1.60 beat Incyte's score of 0.28 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Incyte	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax presently has a consensus target price of $156.69, indicating a potential upside of 81.74%. Incyte has a consensus target price of $127.70, indicating a potential upside of 17.57%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Incyte has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Incyte	$5.14B	4.28	$1.29B	$7.85	13.84

Summary

Incyte beats Abivax on 10 of the 15 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.61B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-14.23	10.21	198.59	19.51
Price / Sales	N/A	1,150.66	562.69	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	13.12	16.95	10.71	6.03
Net Income	-$380.27M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-0.91%	-4.44%	-2.90%	-2.32%
1 Month Performance	-24.09%	-12.51%	-7.38%	-5.29%
1 Year Performance	-11.86%	7.77%	3.04%	-2.94%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	2.5483 of 5 stars	$86.22 -0.8%	$156.69 +81.7%	-9.8%	$7.61B	N/A	N/A	80
ROIV Roivant Sciences	2.7345 of 5 stars	$35.32 +3.2%	$45.64 +29.2%	+105.7%	$25.50B	$8.26M	N/A	721	Analyst Downgrade
BNTX BioNTech	3.881 of 5 stars	$96.62 +5.0%	$125.69 +30.1%	-13.0%	$24.41B	$2.65B	N/A	7,807	Trending News Gap Down
UTHR United Therapeutics	3.9468 of 5 stars	$548.85 +3.0%	$627.31 +14.3%	+23.5%	$23.55B	$3.18B	19.65	1,400	Insider Trade
GMAB Genmab A/S	4.1314 of 5 stars	$37.09 +2.9%	$42.50 +14.6%	+11.9%	$23.14B	$4.13B	29.20	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors

ABVX vs. ROIV, BNTX, UTHR, GMAB, and INCY

How does Abivax compare to Roivant Sciences?

Summary

How does Abivax compare to BioNTech?

Summary

How does Abivax compare to United Therapeutics?

Summary

How does Abivax compare to Genmab A/S?

Summary

How does Abivax compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abivax (ABVX) Competitors

ABVX vs. ROIV, BNTX, UTHR, GMAB, and INCY

How does Abivax compare to Roivant Sciences?

Does the media prefer ABVX or ROIV?

Which has more risk & volatility, ABVX or ROIV?

Do analysts recommend ABVX or ROIV?

Is ABVX or ROIV more profitable?

Which has preferable valuation & earnings, ABVX or ROIV?

Do insiders and institutionals believe in ABVX or ROIV?

Summary

How does Abivax compare to BioNTech?

Do analysts prefer ABVX or BNTX?

Which has preferable earnings & valuation, ABVX or BNTX?

Which has more volatility and risk, ABVX or BNTX?

Is ABVX or BNTX more profitable?

Do insiders & institutionals believe in ABVX or BNTX?

Does the media prefer ABVX or BNTX?

Summary

How does Abivax compare to United Therapeutics?

Which has stronger valuation & earnings, ABVX or UTHR?

Is ABVX or UTHR more profitable?

Do analysts rate ABVX or UTHR?

Do institutionals and insiders believe in ABVX or UTHR?

Does the media prefer ABVX or UTHR?

Which has more risk & volatility, ABVX or UTHR?

Summary

How does Abivax compare to Genmab A/S?

Do analysts rate ABVX or GMAB?

Is ABVX or GMAB more profitable?

Which has more risk and volatility, ABVX or GMAB?

Does the media prefer ABVX or GMAB?

Do institutionals & insiders believe in ABVX or GMAB?

Which has better earnings and valuation, ABVX or GMAB?

Summary

How does Abivax compare to Incyte?

Do insiders & institutionals believe in ABVX or INCY?

Which has more volatility and risk, ABVX or INCY?

Is ABVX or INCY more profitable?

Does the media refer more to ABVX or INCY?

Do analysts rate ABVX or INCY?

Which has stronger earnings & valuation, ABVX or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools